PVPaulina Vaitkienė

Paulina Vaitkienė

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Paulina Vaitkienė has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Aiste Pranckeviciene

    Health Psychology Department, Faculty of Public Health, Medical Academy, Lithuania University of Health Sciences, LT-47181 Kaunas, Lithuania

    1 shared publication
  • Andrius Radziunas

    Department of Neurosurgery, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania

    1 shared publication
  • Arimantas Tamašauskas

    Laboratory of Molecular Neurobiology, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

    1 shared publication
  • Chitra Venugopal

    McMaster Centre for Discovery in Cancer Research, McMaster University, Hamilton, L8S 4M1 ON, Canada

    1 shared publication
  • Daina Skiriutė

    Laboratory of Molecular Neurooncology, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

    1 shared publication
  • Daina Skiriutė

    Laboratory of Molecular Neurooncology, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania

    1 shared publication

Latest Publications

  • Open Access

    Circulating Y-RNAs as New Players in Parkinson Disease and Their Associations with Clinical Measures

    by Violeta Belickienė, Paulina Vaitkienė, Daina Skiriutė, Aistė Pranckevičienė, Andrius Radžiūnas, Greta Žvinakytė, Zbigniev Balion, Chitra Venugopal, Sheila K. Singh, Giedrius Steponaitis

    Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss, and current therapies provide only symptomatic relief. Extracellular vesicles (EVs) have emerged as potential mediators of disease-modifying effects through the transfer of proteins, lipids, and non-coding RNAs. Y-RNAs, a conserved yet understudied class of small non-coding RNAs enriched in EVs, are implicated in fundamental cellular processes such as DNA replication, RNA stability, RNA quality control, and stress-response pathways, and may reflect disease-related cellular states, particularly given that some Y-RNA species are primate-specific. This study aimed to characterize Y-RNA expression in human neural cell models, determine how intracellular levels relate to EV-enriched extracellular profiles, and assess whether serum EV-enriched Y-RNAs show PD-associated alterations with diagnostic relevance and associations with clinical status. Methods: Human neural stem cells and malignant neural cell models were profiled for intracellular Y-RNA expression and EV-enriched extracellular Y-RNAs using EV-enriched RNA preparations. Serum samples from individuals with PD and healthy controls were analyzed to quantify circulating EV-enriched Y-RNAs. Relative Y-RNA abundance and pairwise relative Y-RNA expression measures were compared across cellular models, EV-enriched fractions, and clinical samples to identify disease-related patterns. Results: Y-RNAs displayed distinct relative expression patterns across neural cell models. EV-enriched profiles differed markedly from intracellular abundance, with consistent enrichment of RNY4 and depletion of RNY1 in EV-enriched fractions. These intracellular–extracellular differences were preserved in vesicles released under baseline conditions. In serum EV-enriched fractions, PD was associated with a specific Y-RNA signature: RNY3 related to disease presence, whereas RNY5 correlated with disease duration and severity. Pairwise relative Y-RNA expression measures also provided biologically informative signals both in cell models and patient samples. Conclusions: EV-enriched Y-RNA profiles diverge from intracellular patterns and h exploratory clinical relevance in PD, supporting their potential as markers of disease severity and contributors to disease-related molecular communication.

  • Open Access

    Antisense lncRNA CHROMR is linked to glioma patient survival

    by Dovydas Širvinskas, Giedrius Steponaitis, Rytis Stakaitis, Arimantas Tamašauskas, Paulina Vaitkienė, Daina Skiriutė

    Background: Natural non-coding antisense transcripts (ncNATs) are long non-coding RNAs (lncRNA) transcribed from the opposite strand of a separate protein coding or non-coding gene. As such, ncNATs can increase overlapping mRNA (and the coded protein) levels by stabilizing mRNA, absorbing inhibitory miRNAs and protecting the mRNA from degradation, or conversely decrease mRNA (or protein) levels by directing the mRNA towards degradation or inhibiting protein translation. Recently, growing numbers of ncNATs were shown to be dysregulated in cancerous cells, however, actual impact of ncNATs on cancer progression remains largely unknown. We therefore investigated gene expression levels of natural antisense lncRNA CHROMR (Cholesterol Induced Regulator of Metabolism RNA) and its sense protein coding gene PRKRA (Protein Activator of Interferon Induced Protein Kinase EIF2AK2) in gliomas. Next, we checked CHROMR effect on the survival of glioma patients.Methods: We performed RNA-seq on post-surgical tumor samples from 26 glioma patients, and normal brain tissue. Gene expression in TPM values were extracted for CHROMR and PRKRA genes. These data were validated using the TCGA and GTEx gene expression databases.Results: The gene expression level of ncNAT lncRNA CHROMR in glioma tissue was significantly higher compared to healthy brain tissue, while the expression of its sense counterpart protein coding PRKRA mRNA did not differ between glioma and healthy samples. Survival analysis showed lower survival rates in patients with low mRNA PRKRA/lncRNA CHROMR gene expression ratio compared to high ratio showing a link between lncRNA CHROMR and glioma patient survival prognosis.Conclusion: Here we show that elevated levels of lncRNA CHROMR (i.e., low ratio of mRNA PRKRA/lncRNA CHROMR) is associated with poor prognosis for glioma patients.